Skip to main content

Table 4 Mean changes in HRQoL scores from baseline to study phase completion (week 16) by categories of change in pain ratings, all dose groups combined

From: Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds

 

Categories of change in pain ratings

 

> +10 (n = 31)

+10 to -10 (n = 66)

-11 to -20 (n = 37)

-21 to -40 (n = 28)

< -40 (n = 20)

F

p-value

PRO Instruments

       

SF-36

       

Physical functioning

-2.0 (19.6)

1.7 (13.7)

8.9 (19.7)

13.2 (14.4)

20.3 (22.9)

6.1

0.0001

Role physical

-1.5 (19.7)

4.5 (18.1)

11.0 (20.1)

19.2 (20.6)

26.3 (30.1)

8.0

0.0000

Bodily pain

-7.3 (13.9)

4.0 (13.4)

15.1 (15.0)

20.5 (16.3)

33.9 (22.3)

28.4

0.0000

General health

-4.4 (11.0)

0.6 (13.8)

3.6 (12.8)

7.1 (14.6)

17.8 (13.1)

9.8

0.0000

Vitality

0.4 (13.9)

-0.3 (15.6)

7.6 (19.4)

12.7 (16.4)

28.8 (27.5)

11.8

0.0000

Social functioning

-6.0 (24.8)

-0.6 (18.9)

9.8 (17.9)

10.7 (28.6)

24.4 (39.4)

6.4

0.0001

Role emotional

-7.8 (18.7)

1.4 (23.6)

5.4 (21.4)

10.0 (29.8)

24.6 (32.2)

5.9

0.0002

Mental health

-2.7 (14.6)

2.4 (15.4)

3.5 (17.4)

8.6 (17.2)

15.5 (27.1)

3.9

0.0047

Physical summary

-0.3 (6.3)

1.1 (4.8)

4.6 (5.7)

6.6 (5.0)

9.9 (1.8)

15.1

0.0000

Mental summary

-2.7 (8.3)

0.3 (8.4)

2.0 (8.3)

3.9 (10.9)

10.4 (17.1)

5.9

0.0002

HAQ-DI

0.08 (0.36)

-0.06 (0.33)

-0.26 (0.36)

-0.46 (0.39)

-0.86 (0.51)

21.9

0.0000

FACIT-Fatigue

0.2 (5.7)

0.6 (7.4)

4.2 (5.0)

8.8 (8.2)

10.7 (9.1)

14.0

0.0000